Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a long-term illness with no treatment options that address the disease directly. Solriamfetol is a selective dual norepinephrine-dopamine reuptake inhibitor that promotes wakefulness in obstructive sleep apnea and narcolepsy.
Aims:
This study evaluated the efficacy and safety of solriamfetol for fatigue symptoms in adults with ME/CFS over 8 weeks of treatment.
Methods:
This was a phase 4, double-blind, randomized, placebo-controlled trial of solriamfetol in adults with ME/CFS. Eligible participants (N = 38) were randomly assigned to receive 75 mg (titrated to 150 mg as needed) solriamfetol or placebo. Participants completed a battery of assessments at weekly visits. The primary outcome was Fatigue Symptom Inventory (FSI) scores, and the secondary outcome measure was Behavioral Rating Inventory of Executive Function for Adults (BRIEF-A), at Weeks 6 and 8. T-tests assessed the differences in mean change from baseline between solriamfetol and placebo. Adverse events were monitored throughout the study.
Results:
At Week 8 (p = 0.039), but not Week 6 (p = 0.270), solriamfetol improved FSI severity compared to placebo. On the BRIEF-A global executive composite, solriamfetol improved more than placebo at Week 8 (p = 0.012), driven by improved metacognition index (p = 0.004), but not behavioral regulation index (p = 0.574). Solriamfetol was well tolerated, with most common AEs being sleep loss and headaches.
Conclusions:
Solriamfetol demonstrated good safety and efficacy in improving fatigue and executive functioning in patients with ME/CFS. As a dual norepinephrine-dopamine reuptake inhibitor and wakefulness-promoting factors, solriamfetol has the potential to improve fatigue symptoms of ME/CFS.
ArnoldLMBlomTJWelgeJA, et al. (2015) A randomized, placebo-controlled, double-blinded trial of duloxetine in the treatment of general fatigue in patients with chronic fatigue syndrome. Psychosomatics56(3): 242–253. DOI: 10.1016/j.psym.2014.12.003
2.
BerkMNgFDoddS, et al. (2008) The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. Journal of Evaluation in Clinical Practice, 14(6): 979–983. DOI: 10.1111/j.1365-2753.2007.00921.x
BlockmansDPersoonsPVan HoudenhoveB, et al. (2006) Does methylphenidate reduce the symptoms of chronic fatigue syndrome?The American Journal of Medicine119(2): 167.e23–30. DOI: 10.1016/j.amjmed.2005.07.047
5.
BreitbartWAlici-EvcimenY (2007) Update on psychotropic medications for cancer-related fatigue. Journal of the National Comprehensive Cancer Network: JNCCN5(10): 1081–1091. DOI: 10.6004/jnccn.2007.0089
6.
BusnerJTargumSD (2007) The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry4(7): 28–37.
7.
CarruthersBMvan de SandeMIDe MeirleirKL, et al. (2011) Myalgic encephalomyelitis: International Consensus Criteria. Journal of Internal Medicine270(4): 327–338. DOI: 10.1111/j.1365-2796.2011.02428.x
8.
CarterLPHenningfieldJEWangYG, et al. (2018) A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. Journal of Psychopharmacology32(12): 1351–1361. DOI: 10.1177/0269881118796814
9.
Castro-MarreroJSáez-FrancàsNSantilloD, et al. (2017) Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: All roads lead to Rome. British Journal of Pharmacology174(5): 345–369. DOI: 10.1111/bph.13702
10.
Cortes RiveraMMastronardiCSilva-AldanaCT, et al. (2019) Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A comprehensive review. Diagnostics9(3): 91. DOI: 10.3390/diagnostics9030091
11.
FaraoneSV (2018) The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neuroscience and Biobehavioral Reviews87: 255–270. DOI: 10.1016/j.neubiorev.2018.02.001
12.
FoleyKFDeSantyKPKastRE (2006) Bupropion: Pharmacology and therapeutic applications. Expert Review of Neurotherapeutics6(9): 1249–1265. DOI: 10.1586/14737175.6.9.1249
13.
ForkmannTSchererABoeckerM, et al. (2011) The Clinical Global Impression Scale and the influence of patient or staff perspective on outcome. BMC Psychiatry11(83): 1–7. DOI: 10.1186/1471-244X-11-83
14.
GhaliALacoutCFortratJ-O, et al. (2022) Factors influencing the prognosis of patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Diagnostics12(10): 2540. DOI: 10.3390/diagnostics12102540
15.
GioiaGAIsquithPKGuySC, et al. (2000) TEST REVIEW behavior rating inventory of executive function. Child Neuropsychology6(3): 235–238. DOI: 10.1076/chin.6.3.235.3152
16.
GioiaGAIsquithPKRetzlaffPD, et al. (2002) Confirmatory factor analysis of the Behavior Rating Inventory of Executive Function (BRIEF) in a clinical sample. Child Neuropsychology8(4): 249–257. DOI: 10.1076/chin.8.4.249.13513
17.
GlassfordJAG (2017) The neuroinflammatory etiopathology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Frontiers in Physiology8: 88. DOI: 10.3389/fphys.2017.00088
18.
GoertzelBNPennachinCde Souza CoelhoL, et al. (2006) Combinations of single nucleotide polymorphisms in neuroendocrine effector and receptor genes predict chronic fatigue syndrome. Pharmacogenomics7(3): 475–483. DOI: 10.2217/14622416.7.3.475
19.
GravesBSPatelMNewgentH, et al. (2024) Chronic fatigue syndrome: Diagnosis, treatment, and future direction. Cureus16(10): e70616. DOI: 10.7759/cureus.70616
20.
GuyW (1976) ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs.
21.
HannDMDennistonMMBakerF (2000) Measurement of fatigue in cancer patients: Further validation of the Fatigue Symptom Inventory. Quality of Life Research9(7): 847–854. DOI: 10.1023/A:1008900413113
22.
HannDMJacobsenPBAzzarelloLM, et al. (1998) Measurement of fatigue in cancer patients: Development and validation of the Fatigue Symptom Inventory. Quality of Life Research7(4): 301–310. https://www.jstor.org/stable/4034523
23.
HudsonJIArnoldLMBradleyLA, et al. (2009) What makes patients with fibromyalgia feel better? correlations between patient global impression of improvement and changes in clinical symptoms and function: A pooled analysis of 4 randomized placebo-controlled trials of duloxetine. The Journal of Rheumatology36(11): 2517–2522. DOI: 10.3899/jrheum.090139
Kreijkamp-KaspersSBrenuEWMarshallS, et al. (2020) Treating chronic fatigue syndrome: A study into the scientific evidence for pharmacological treatments. Australian Family Physician40(11): 907–912. http://hdl.handle.net/1854/LU-1991684
26.
LeonACOlfsonMPorteraL, et al. (1997) Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. The International Journal of Psychiatry in Medicine27(2): 93–105. DOI: 10.2190/T8EM-C8YH-373N-1UWD
27.
LeonACShearMKKlermanGL, et al. (1993) A comparison of symptom determinants of patient and clinician global ratings in patients with panic disorder and depression. Journal of Clinical Psychopharmacology13(5): 327–331.
28.
LeuchtSEngelRR (2006) The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacology31(2): 406–412. DOI: 10.1038/sj.npp.1300873
29.
LiD-QLiZ-CDaiZ-Y (2015) Selective serotonin reuptake inhibitor combined with Dengzhanshengmai capsule improves the fatigue symptoms: A 12-week open-label pilot study. International Journal of Clinical and Experimental Medicine8(7): 11811–11817. https://pmc.ncbi.nlm.nih.gov/articles/PMC4565405/
30.
LorussoLMikhaylovaSVCapelliE, et al. (2009) Immunological aspects of chronic fatigue syndrome. Autoimmunity Reviews8(4): 287–291. DOI: 10.1016/j.autrev.2008.08.003
31.
LubaczewskiSShepherdJFayyadR, et al. (2014) Real-world disparities between patient- and clinician-reported outcomes: Results from a disease-specific program in depression and anxiety. Professional Case Management19(2): 63–74. DOI: 10.1097/NCM.0000000000000015
32.
MaesMTwiskFNMKuberaM, et al. (2012) Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Increased interleukin-1, tumor necrosis factor-α, PMN-elastase, lysozyme and neopterin. Journal of Affective Disorders136(3): 933–939. DOI: 10.1016/j.jad.2011.09.004
33.
MeyerBNguyenCBTMoenA, et al. (2015) Maintenance of Chronic Fatigue Syndrome (CFS) in young CFS patients is associated with the 5-HTTLPR and SNP rs25531 A > G genotype. PLOS ONE10(10): e0140883. DOI: 10.1371/journal.pone.0140883
34.
MosherCESecintiEJohnsSA, et al. (2022) Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors. Journal of Patient-Reported Outcomes6(1): 82. DOI: 10.1186/s41687-022-00488-1
35.
NakatomiYMizunoKIshiiA, et al. (2014) Neuroinflammation in patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An 11C-(R)-PK11195 PET study. Journal of Nuclear Medicine55(6): 945–950. DOI: 10.2967/jnumed.113.131045
36.
NatelsonBHCheuJHillN, et al. (1998) Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome. Neuropsychobiology37(3): 150–154. DOI: 10.1159/000026494
NodaMIfukuMHossainMS, et al. (2018) Glial activation and expression of the serotonin transporter in Chronic Fatigue Syndrome. Frontiers in Psychiatry9: 589. DOI: 10.3389/fpsyt.2018.00589
39.
PapakostasGINuttDJHallettLA, et al. (2006) Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biological Psychiatry60(12): 1350–1355. DOI: 10.1016/j.biopsych.2006.06.015
40.
PetterssonAModinSWahlströmR, et al. (2018) The Mini-International Neuropsychiatric Interview is useful and well accepted as part of the clinical assessment for depression and anxiety in primary care: A mixed-methods study. BMC Family Practice19(1): 19. DOI: 10.1186/s12875-017-0674-5
41.
RamakrishnanDFarhatLCVattimoEFQ, et al. (2024) An evaluation of treatment response and remission definitions in adult obsessive-compulsive disorder: A systematic review and individual-patient data meta-analysis. Journal of Psychiatric Research173: 387–397. DOI: 10.1016/j.jpsychires.2024.03.044
42.
RandallDCCaffertyFHShneersonJM, et al. (2005) Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome. Journal of Psychopharmacology19(6): 647–660. DOI: 10.1177/0269881105056531
43.
RichmanSMorrisMCBroderickG, et al. (2019) Pharmaceutical interventions in the treatment of chronic fatigue syndrome: a literature-based commentary. Clinical Therapeutics41(5): 798–805. DOI: 10.1016/j.clinthera.2019.02.011
44.
RothRMErdodiLAMcCullochLJ, et al. (2015) Much ado about norming: The behavior rating inventory of executive function. Child Neuropsychology21(2): 225–233. DOI: 10.1080/09297049.2014.897318
45.
RuoffCSwickTJDoekelR, et al. (2016) Effect Of Oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: A Phase 2b study. Sleep39(7): 1379–1387. DOI: 10.5665/sleep.5968
46.
SandlerCXLloydAR (2020) Chronic fatigue syndrome: Progress and possibilities. Medical Journal of Australia212(9): 428–433. DOI: 10.5694/mja2.50553
47.
SchweitzerPKRosenbergRZammitGK, et al. (2019) Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A randomized controlled trial. American Journal of Respiratory and Critical Care Medicine199(11): 1421–1431. DOI: 10.1164/rccm.201806-1100OC
48.
SheehanKHSheehanDV (2008) Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale. International Clinical Psychopharmacology23(2): 70–83. DOI: 10.1097/YIC.0b013e3282f2b4d6
49.
SmithAKDimulescuIFalkenbergVR, et al. (2008) Genetic evaluation of the serotonergic system in chronic fatigue syndrome. Psychoneuroendocrinology33(2): 188–197. DOI: 10.1016/j.psyneuen.2007.11.001
50.
SmithMEBHaneyEMcDonaghM, et al. (2015) Treatment of myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review for a National Institutes of Health Pathways to Prevention Workshop. Annals of Internal Medicine162(12): 841–850. DOI: 10.7326/M15-0114
51.
ThorpyMJShapiroCMayerG, et al. (2019) A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Annals of Neurology85(3): 359–370. DOI: 10.1002/ana.25423
52.
TomasCNewtonJWatsonS (2013) A review of hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome. International Scholarly Research Notices2013(1): 784520. DOI: 10.1155/2013/784520
53.
TourbahAPapeixCTourniaireP, et al. (2020) Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: The ESGILE study. Multiple Sclerosis and Related Disorders46: 102433. DOI: 10.1016/j.msard.2020.102433
54.
United States: Health and Human Services Department: Office of Public Health and Science, et al. (2014) Diagnosis and Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Health and Human Services Department. Available at: https://purl.fdlp.gov/GPO/gpo142110 (accessed 17 July 2025)
55.
ViktrupLHayesRPWangP, et al. (2012) Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. BMC Urology12: 30. DOI: 10.1186/1471-2490-12-30
56.
WeaverTEDrakeCLBenesH, et al. (2020) Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial. Annals of the American Thoracic Society17(8): 998–1007. DOI: 10.1513/AnnalsATS.202002-136OC
57.
WilliamsDAArnoldLM (2011) Measures of fibromyalgia: Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFI-20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Self-Report Questionnaire (MASQ). Arthritis Care & Research63(11): S86. DOI: 10.1002/acr.20531
58.
WyllerVBVitelliVSulheimD, et al. (2016) Altered neuroendocrine control and association to clinical symptoms in adolescent chronic fatigue syndrome: A cross-sectional study. Journal of Translational Medicine14: 121. DOI: 10.1186/s12967-016-0873-1
59.
YoungJL (2013) Use of lisdexamfetamine dimesylate in treatment of executive functioning deficits and chronic fatigue syndrome: A double blind, placebo-controlled study. Psychiatry Research207(1): 127–133. DOI: 10.1016/j.psychres.2012.09.007
60.
YoungJLRedmondJC (2007) Fibromylagia, chronic fatigue, and adult attention deficit hyperactivity disorder in the adult: A case study. Psychopharmacology Bulletin40(1): 118–126.
61.
ZhengBChenFWangJ, et al. (2023) The prevalence and correlated factors of occupational stress, cumulative fatigue, and musculoskeletal disorders among information technology workers: A cross-sectional study in Chongqing, China. Healthcare11(16): 2322. DOI: 10.3390/healthcare11162322
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
